MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-05-2025
AxoGen General and Administrative Expenses 2011-2025 | AXGN
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses AxoGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 39 M | 38.4 M | 40.9 M | 32.3 M | 26.4 M | 31.3 M | 23.1 M | 14.7 M | 10.1 M | 8.42 M | 6.95 M | 5.72 M | 5.22 M | 4.32 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 40.9 M | 4.32 M | 20.5 M |
Quarterly General and Administrative Expenses AxoGen
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.69 M | 9.46 M | - | 10.8 M | 9.42 M | 9.96 M | - | 9.87 M | 10.6 M | 10.1 M | - | 8.8 M | 9.4 M | 9.62 M | - | 7.88 M | 8.67 M | 8.36 M | - | 6.82 M | 6.4 M | 5.5 M | - | 7.74 M | 7.38 M | 9.2 M | - | 6.07 M | 5.67 M | 5.01 M | - | 3.78 M | 3.38 M | 3.5 M | - | 2.48 M | 2.74 M | 2.14 M | - | 2.21 M | 1.98 M | 1.91 M | - | 1.65 M | 1.71 M | 1.89 M | - | 1.23 M | 1.4 M | 1.61 M | - | 1.39 M | 1.15 M | 1.23 M | - | 1.3 M | 1.2 M | 722 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.8 M | 722 K | 5.29 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B |  USA |
 |
Abiomed
ABMD
|
334 M | - | - | $ 17.2 B | USA |
 |
Acutus Medical
AFIB
|
14.1 M | - | -26.83 % | $ 2.62 M | USA |
 |
Apyx Medical Corporation
APYX
|
22.2 M | $ 3.79 | -1.81 % | $ 131 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bio-Rad Laboratories
BIO
|
814 M | $ 306.68 | -0.46 % | $ 8.65 B | USA |
 |
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | USA |
 |
BioSig Technologies
BSGM
|
11.6 M | - | 37.08 % | $ 85.7 M | USA |
 |
Bruker Corporation
BRKR
|
894 M | $ 45.79 | 1.46 % | $ 6.82 K | USA |
 |
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | USA |
 |
Abbott Laboratories
ABT
|
11.7 B | $ 128.4 | 2.33 % | $ 223 B | USA |
 |
Boston Scientific Corporation
BSX
|
5.98 B | $ 92.01 | -0.6 % | $ 135 B | USA |
 |
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | USA |
 |
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | USA |
 |
EDAP TMS S.A.
EDAP
|
5.9 M | $ 3.16 | 9.55 % | $ 118 M |  France |
 |
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M | USA |
 |
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M |  Canada |
 |
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | USA |
 |
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | USA |
 |
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
163 M | $ 9.59 | -2.74 % | $ 689 M | Israel |
 |
InMode Ltd.
INMD
|
8.41 M | $ 14.36 | -1.03 % | $ 1.14 B | Israel |
 |
IRIDEX Corporation
IRIX
|
8.75 M | $ 0.98 | 5.89 % | $ 15.8 M | USA |
 |
IRadimed Corporation
IRMD
|
15.9 M | $ 96.66 | 0.44 % | $ 1.22 B | USA |
 |
Second Sight Medical Products
EYES
|
806 K | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
1.76 B | $ 163.43 | -1.21 % | $ 12.2 B | USA |
 |
Accuray Incorporated
ARAY
|
47.9 M | $ 1.05 | -0.94 % | $ 108 M | USA |
 |
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
12 M | $ 12.55 | -1.3 % | $ 339 M | USA |
 |
FONAR Corporation
FONR
|
23.5 M | $ 14.83 | 0.54 % | $ 97.2 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
117 M | $ 40.28 | -1.33 % | $ 1.24 B | USA |
 |
LivaNova PLC
LIVN
|
526 M | $ 62.88 | 0.21 % | $ 3.41 B |  Britain |
 |
OrthoPediatrics Corp.
KIDS
|
103 M | $ 17.67 | 0.4 % | $ 408 M | USA |
 |
Globus Medical
GMED
|
981 M | $ 86.48 | -0.24 % | $ 11.7 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
717 M | $ 13.54 | 0.86 % | $ 1.04 B | USA |
|
LENSAR
LNSR
|
26.5 M | $ 11.6 | 0.78 % | $ 134 M | USA |
 |
Aziyo Biologics
AZYO
|
14.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
Alphatec Holdings
ATEC
|
450 M | $ 19.95 | -0.08 % | $ 2.85 B | USA |
 |
Aethlon Medical
AEMD
|
3.24 M | $ 3.15 | -7.35 % | $ 4.92 M | USA |
 |
Establishment Labs Holdings
ESTA
|
140 M | $ 72.06 | -0.63 % | $ 2.03 B |  Costa-rica |